LeMaitre Vascular Future Growth
Future criteria checks 1/6
LeMaitre Vascular is forecast to grow earnings and revenue by 12.2% and 8.6% per annum respectively. EPS is expected to grow by 10.5% per annum. Return on equity is forecast to be 13.8% in 3 years.
Key information
12.2%
Earnings growth rate
10.5%
EPS growth rate
Medical Equipment earnings growth | 17.0% |
Revenue growth rate | 8.6% |
Future return on equity | 13.8% |
Analyst coverage | Good |
Last updated | 20 Dec 2024 |
Recent future growth updates
Recent updates
LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) 26% Price Boost Is Out Of Tune With Earnings
Nov 24LeMaitre Vascular: The Market Is Catching On To This Dividend Growth Story
Nov 03LeMaitre Vascular, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Nov 02Is LeMaitre Vascular, Inc. (NASDAQ:LMAT) Potentially Undervalued?
Oct 08Investors Met With Slowing Returns on Capital At LeMaitre Vascular (NASDAQ:LMAT)
Sep 17LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Price In Tune With Earnings
Sep 04If EPS Growth Is Important To You, LeMaitre Vascular (NASDAQ:LMAT) Presents An Opportunity
Aug 22LeMaitre Vascular: A Small Cap With Best-In-Industry Growth
Jul 23Is LeMaitre Vascular, Inc. (NASDAQ:LMAT) Worth US$85.0 Based On Its Intrinsic Value?
Jul 12Is There Now An Opportunity In LeMaitre Vascular, Inc. (NASDAQ:LMAT)?
Jun 18Return Trends At LeMaitre Vascular (NASDAQ:LMAT) Aren't Appealing
Jun 05LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Popularity With Investors Is Clear
May 02Is Now The Time To Put LeMaitre Vascular (NASDAQ:LMAT) On Your Watchlist?
Apr 04Calculating The Fair Value Of LeMaitre Vascular, Inc. (NASDAQ:LMAT)
Feb 29What Does LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Share Price Indicate?
Jan 19Returns On Capital At LeMaitre Vascular (NASDAQ:LMAT) Paint A Concerning Picture
Oct 27Is It Too Late To Consider Buying LeMaitre Vascular, Inc. (NASDAQ:LMAT)?
Oct 11Does LeMaitre Vascular (NASDAQ:LMAT) Deserve A Spot On Your Watchlist?
Aug 30The Returns On Capital At LeMaitre Vascular (NASDAQ:LMAT) Don't Inspire Confidence
Jul 06Is LeMaitre Vascular, Inc. (NASDAQ:LMAT) Worth US$62.3 Based On Its Intrinsic Value?
May 20Should You Think About Buying LeMaitre Vascular, Inc. (NASDAQ:LMAT) Now?
Mar 12Should You Think About Buying LeMaitre Vascular, Inc. (NASDAQ:LMAT) Now?
Oct 23Calculating The Fair Value Of LeMaitre Vascular, Inc. (NASDAQ:LMAT)
Oct 05LeMaitre Vascular (NASDAQ:LMAT) Could Be Struggling To Allocate Capital
Sep 13LeMaitre Vascular: Reiterate Buy Thesis Following Strong Q2 Numbers
Sep 08LeMaitre Vascular goes ex dividend tomorrow
Aug 23Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 259 | 56 | 59 | 66 | 7 |
12/31/2025 | 240 | 50 | 52 | 57 | 10 |
12/31/2024 | 220 | 44 | 34 | 46 | 10 |
9/30/2024 | 213 | 41 | 33 | 40 | N/A |
6/30/2024 | 206 | 38 | 32 | 37 | N/A |
3/31/2024 | 200 | 34 | 33 | 40 | N/A |
12/31/2023 | 193 | 30 | 29 | 37 | N/A |
9/30/2023 | 186 | 27 | 23 | 30 | N/A |
6/30/2023 | 177 | 25 | 19 | 26 | N/A |
3/31/2023 | 169 | 21 | 18 | 23 | N/A |
12/31/2022 | 162 | 21 | 22 | 25 | N/A |
9/30/2022 | 160 | 21 | 24 | 26 | N/A |
6/30/2022 | 160 | 22 | 29 | 33 | N/A |
3/31/2022 | 158 | 27 | 29 | 34 | N/A |
12/31/2021 | 154 | 27 | 30 | 35 | N/A |
9/30/2021 | 152 | 28 | 39 | 44 | N/A |
6/30/2021 | 151 | 29 | 40 | 44 | N/A |
3/31/2021 | 135 | 24 | 37 | 40 | N/A |
12/31/2020 | 129 | 21 | 32 | 35 | N/A |
9/30/2020 | 122 | 19 | 23 | 26 | N/A |
6/30/2020 | 115 | 16 | 13 | 17 | N/A |
3/31/2020 | 119 | 18 | 12 | 16 | N/A |
12/31/2019 | 117 | 18 | 10 | 14 | N/A |
9/30/2019 | 115 | 19 | 12 | 15 | N/A |
6/30/2019 | 111 | 18 | 12 | 15 | N/A |
3/31/2019 | 108 | 23 | 12 | 16 | N/A |
12/31/2018 | 106 | 23 | 16 | 20 | N/A |
9/30/2018 | 103 | 21 | 16 | 20 | N/A |
6/30/2018 | 104 | 22 | N/A | 24 | N/A |
3/31/2018 | 103 | 18 | N/A | 24 | N/A |
12/31/2017 | 101 | 17 | N/A | 23 | N/A |
9/30/2017 | 98 | 15 | N/A | 20 | N/A |
6/30/2017 | 96 | 14 | N/A | 18 | N/A |
3/31/2017 | 93 | 12 | N/A | 18 | N/A |
12/31/2016 | 89 | 11 | N/A | 17 | N/A |
9/30/2016 | 86 | 11 | N/A | 17 | N/A |
6/30/2016 | 82 | 9 | N/A | 14 | N/A |
3/31/2016 | 79 | 9 | N/A | 13 | N/A |
12/31/2015 | 78 | 8 | N/A | 11 | N/A |
9/30/2015 | 76 | 7 | N/A | 10 | N/A |
6/30/2015 | 74 | 6 | N/A | 9 | N/A |
3/31/2015 | 73 | 5 | N/A | 7 | N/A |
12/31/2014 | 70 | 4 | N/A | 6 | N/A |
9/30/2014 | 70 | 3 | N/A | 4 | N/A |
6/30/2014 | 67 | 3 | N/A | 4 | N/A |
3/31/2014 | 65 | 2 | N/A | 4 | N/A |
12/31/2013 | 64 | 3 | N/A | 5 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LMAT's forecast earnings growth (12.2% per year) is above the savings rate (2.6%).
Earnings vs Market: LMAT's earnings (12.2% per year) are forecast to grow slower than the US market (15.2% per year).
High Growth Earnings: LMAT's earnings are forecast to grow, but not significantly.
Revenue vs Market: LMAT's revenue (8.6% per year) is forecast to grow slower than the US market (9.1% per year).
High Growth Revenue: LMAT's revenue (8.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: LMAT's Return on Equity is forecast to be low in 3 years time (13.8%).
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/22 02:24 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
LeMaitre Vascular, Inc. is covered by 22 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Michael Petusky | Barrington Research Associates, Inc. |
Raymond Myers | Benchmark Company |
Jan Wald | Benchmark Company |